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Abstract
Background: Effects of long-term glucose load on peritoneal dialysis (PD) patient safety and outcomes have seldom been
reported. This study demonstrates the influence of long-term glucose load on patient and technique survival.
Methods: We surveyed 173 incident PD patients. Long-term glucose load was evaluated by calculating the average
dialysate glucose concentration since initiation of PD. Risk factors were assessed by fitting Cox’s models with repeatedly
measured time-dependent covariates.
Results: We noted that older age, higher glucose concentration, and lower residual renal function (RRF) were significantly
associated with a worse patient survival. We found that female gender, absence of diabetes, lower glucose concentration,
use of icodextrin, higher serum high density lipoprotein cholesterol, and higher RRF were significantly associated with a
better technique survival.
Conclusions: Long-term glucose load predicted mortality and technique failure in chronic PD patients. These findings
emphasize the importance of minimizing glucose load in PD patients.
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Introduction
Glucose is the main osmotic agents providing ultrafiltration (UF)
to peritoneal dialysis (PD) patients [1], however, a high glucose
load may cause peritoneal damage, hyperglycemia, hyperinsulin-
emia, dyslipidemia, oxidative stress, and increased incidences of
metabolic syndrome, as well as cardiovascular diseases (CVD)
[2,3,4]. We recently reported that higher initial glucose load,
defined as the average dialysate glucose concentration prescribed
in the first 6 months of PD therapy, predicted a worse PD
technique survival [1]. In addition, we also identified that patients
with diabetes mellitus (DM), high body mass index (BMI), and low
residual renal function (RRF) tend to have a high dialysate glucose
load during long-term PD therapy [5]. Regarding long-term
patient safety, the accumulative effects from glucose load have
rarely been reported. In this retrospective 7-year cohort study of
chronic PD patients, we analyze the accumulative effects of long-
term glucose load on patient outcomes by applying repeatedly
measured time-dependent covariates in survival analysis.
Methods
Ethics Statement
The Institutional Review Board of National Taiwan University
Hospital approved the retrospective cohort study. Written
informed consent was not needed because the study retrospectively
collected available medical records in the hospital. The Institu-
tional Review Board specifically granted a waiver for the ‘‘no
consent needed’’.
Study participants: inclusion and exclusion criteria
202 patients initiated PD therapy at our PD center between
September 2001 and January 2006. We excluded those who were
younger than 18 years old (n=4) or had active malignancy (n=3).
Patients who had a PD technique survival shorter than 6 months
(n=10) or had undergone PD previously (n=12) were also
excluded. A total of 173 end-stage renal disease (ESRD) patients
were enrolled in our study and were followed until February 2008.
The mean follow-up period was 42.0617.2 (range 6–78) months.
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gender, and annual data of comorbid diseases, body height, body
weight, RRF, peritoneal transport characteristics and solute
clearance, cardiothoracic ratio (CTR), and blood laboratory
exams. Comorbid diseases included DM, CVD, and chronic
hepatic diseases. Patients with a history of stroke, coronary or
peripheral artery diseases, or left ventricular ejection fraction less
than 30% were considered to have CVD [5,6]. Chronic hepatic
diseases included liver cirrhosis and chronic viral hepatitis [7].
Definitions of patient survival and PD technique survival
The primary outcome of this study was actuarial patient survival
and the secondary outcome was PD technique survival. In the
analysis of patient survival, the causes of drop-out were classified as
death, renal transplantation, and hospital transfer. Because long-
term survival is much better for renal transplant recipients than
patients who remain on dialysis [8], renal transplantation, as well
as hospital transfer, were considered as censoring events in the
analysis of patient survival. In the analysis of PD technique
survival, the reasons for terminating PD were categorized as
hospital transfer, renal transplantation, death, and switching to
hemodialysis (HD). Among them, events of switching to HD were
recognized as PD technique failure, while the others were
regarded as censoring events.
PD regimens and calculation of glucose load
The PD regimen and modality for each patient were evaluated
and prescribed in our PD unit during monthly follow-up. We
reviewed the detailed PD regimen of each patient. Our evaluations
for glucose exposure included glucose weight and glucose load.
Glucose weight was defined as the sum of the products of glucose
concentration and the volume for each exchange of glucose
solution (DianealH; Baxter Healthcare Corporation, Deerfield, IL,
U.S.A.) over a time period [9], whereas glucose load was
calculated as the average dialysate glucose concentration (i.e.,
[total glucose weight]/[total volume of glucose solution]) over a
time period [10,11]. The administered volume of icodextrin
solution (ExtranealH; Baxter Healthcare) and amino acid solution
(NutrinealH; Baxter Healthcare) for each patient was also
evaluated.
Laboratory examinations and peritoneal dialysis
assessments
The blood for laboratory exams was drawn after patients had
fasted for at least 8 hours. We evaluated dialysate-to-plasma ratio
of creatinine (D/P Cre) and UF volume by the peritoneal
equilibration test (PET) [12]. We measured peritoneal solute
clearance by weekly peritoneal Kt/V, evaluated RRF based on
weekly renal Kt/V, and estimated protein intake by normalized
protein nitrogen appearance (nPNA) [13]. All biochemical and
hematological tests were performed with automatic analyzers.
Statistical analyses
Data are expressed as mean 6 standard deviation (SD) or
frequency and percentage, unless otherwise indicated. As descrip-
tive analysis, univariate analyses were performed by using two-
sample t tests, one-way analysis of variance (ANOVA), Pearson’s
chi-square test, or Fisher’s exact test, as appropriate. In
multivariate analysis, the risk factors of mortality and PD
technique failure were assessed by fitting two different Cox’s
models with repeatedly measured time-dependent covariates using
the counting process approach. The repeatedly measured time-
dependent covariates included body weight, comorbidity status,
dialysate prescription, PD modality, laboratory blood exams,
peritoneal transport, estimated protein intake, and solute clearance
by the peritoneum and kidneys. Among them, each subject’s
dialysate prescription was represented by (1) the accumulative
glucose exposure and (2) the accumulative volumes of icodextrin
solution and amino acid solution, from the time of PD initiation to
each time at which a PD technique failure or death occurred in the
Cox’s models for PD technique failure or mortality.
Next, the predictors of each year’s annual average dialysate
glucose concentration over the 6-year follow-up period were
examined. Since the missing data in the repeated-measurements of
glucose concentration at later times was most likely due to PD
technique failure, 6 separate multiple linear regression models
were fitted to the data of the subjects who were still at risk in the
beginning of each year.
To assure the quality of the analysis results, we applied basic
model-fitting techniques, including stepwise variable selection,
goodness-of-fit assessment, and regression diagnostics (e.g.,
residual analysis, detection of influential cases, and checks for
multicollinearity), in our regression analysis. The stepwise variable
selection procedure (with iterations between the forward and
backward steps) was applied to obtain the candidate final
regression model. All the univariate significant and non-significant
relevant covariates and some of their interactions were put on the
variable list to be selected. The significance levels for entry and for
stay were set to 0.15 or larger. Since the statistical testing at each
step of the stepwise variable selection procedure was conditioning
on the other covariates in the regression model, the concern about
multiple analyses is minor. We used the variance inflation factor to
detect the potential multicollinearity problem. A grid search
method was applied to discover appropriate cut-off points for
representing nonlinear effects of some continuous covariates. A
two-sided P value #0.05 was considered statistically significant.
The statistical analyses were conducted using SAS software,
version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
There were 87 men and 86 women enrolled in our study with a
mean age of 54.6615.6 years at PD initiation. Patients with longer
technique survivals had higher BMI, higher serum levels of total
cholesterol, triglyceride (TG), albumin, and creatinine (Table 1).
We noted a trend of a decrease in RRF with increasing peritoneal
Kt/V among patients who had more prolonged PD therapy.
Moreover, these patients were prescribed with higher doses of
icodextrin solution and showed a higher UF volume in later years
(Table 1). Patients with longer overall survivals had higher BMI
and higher serum levels of total cholesterol, TG, albumin, and
creatinine (Table 2). During the study period, 4 cases of new-onset
DM were diagnosed, and we considered the change in DM status
as a repeatedly measured time-dependent covariate in the
regression analysis.
Patient survival analysis
By the end of the follow-up, there were 60 dropouts, including
31 deaths, 20 renal transplantations, and 9 patients transferred to
other hospitals. The major causes of death included infectious
diseases (64.5%) and CVD (12.9%). The annual patient survival
rates by using the Kaplan-Meier method were 94.7%, 90.5%,
85.5%, 78.0%, and 75.5% at the beginning of year-2, year-3, year-
4, year-5, and year-6, respectively. Kaplan-Meier survival curves
showed a significant worse patient survival in the subjects with
higher glucose load (Figure 1A, P=0.03). The mean patient
Safety Issues of Chronic Glucose Load
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repeatedly measured time-dependent covariates, we found that
older age, higher glucose load, lower RRF, higher blood urea
nitrogen (BUN), and lower serum creatinine were significantly
associated with a worse patient survival (Table 3). The presence of
CVD had a borderline significant influence on patient survival
(Table 3), and the positive association between the presence of
CVD and DM was highly significant (odds ratio=7.224,
P,0.001). This could explain why only the presence of CVD,
but not also DM, was significant in patient survival analysis.
PD technique survival analysis
By the end of the follow-up, there were 42 PD technique
failures, including peritonitis (42.9%), UF failure (21.4%), exit site
infection (19.0%), and inadequate solute clearance (14.3%). Events
of random censorings included 20 renal transplantations, 3
hospital transfers, and 19 deaths (mainly due to infectious diseases
and CVD). The annual PD technique survival rates by using the
Kaplan-Meier method were 95.7%, 88.5%, 79.8%, 71.6%, and
56.4% at the beginning of year-2, year-3, year-4, year-5, and year-
6, respectively. Kaplan-Meier survival curves showed a borderline
significant worse technique survival in the subjects with higher
glucose load (Figure 1B, P=0.057). The mean technique survival
time was 58.862.1 months. By fitting Cox’s models with
repeatedly measured time-dependent covariates, we found that
male gender, the presence of DM, higher glucose load, lower
RRF, and lower serum high-density lipoprotein (HDL) were
significantly associated with a worse technique survival (Table 3).
Table 1. Demographic and clinical data of patients who remained on PD at the beginning of each year.
Treatment Year
Variable First year Second year Third year Fourth year Fifth year Sixth year
Patient number 173 151 133 86 49 13
Gender(M:F) 87 : 86 75 : 76 64 : 69 37 : 49 22 : 27 5 : 8
Baseline age (years) 54.6 6 15.6 53.3 6 14.7 53.2 6 14.0 51.0 6 12.0 50.8 6 9.2 52.0 6 8.6
Glucose concentration (%)* 1.81 6 0.26 1.79 6 0.33 1.80 6 0.39 1.81 6 0.42 1.76 6 0.71 1.90 6 0.68
Glucose weight (Kg/month)** 4.9 6 1.5 4.9 6 1.7 5.0 6 1.7 5.1 6 1.9 4.8 6 2.3 4.3 6 1.9
Icodextrin solution (L/month)**,
j 3.6 6 14.1 7.2 6 18.9 12.5 6 24.9 9.8 6 21.4 11.5 6 21.1 25.5 6 25.8
Amino acid solution (L/month)** 1.3 6 5.4 2.2 6 8.0 2.0 6 8.7 0.7 6 3.2 0.8 6 2.7 0.0 6 0.0
Body mass index (Kg/m
2)
j 21.6 6 3.2 22.8 6 3.4 23.0 6 3.3 22.9 6 2.8 23.0 6 2.4 22.6 6 2.8
Comorbid diseases
Diabetes mellitus 37 (21.4) 29 (19.2) 22 (16.5) 10 (11.6) 5 (10.2) 3 (23.1)
Cardiovascular diseases 64 (37.0) 52 (34.4) 41 (30.8) 24 (27.9) 10 (20.4) 5 (38.5)
D/P Cre 0.63 6 0.10 0.62 6 0.10 0.61 6 0.10 0.61 6 0.10 0.62 6 0.10 0.65 6 0.07
Ultrafiltration volume (ml)***,
j 278 6 187 333 6 173 376 6 332 347 6 221 441 6 265 456 6 154
PD modality (CAPD:APD) 144 : 29 121 : 30 97 : 36 61 : 25 36 : 13 12 : 1
Weekly peritoneal Kt/V
j 1.71 6 0.36 1.85 6 0.33 1.94 6 0.27 1.96 6 0.28 2.09 6 0.29 2.09 6 0.33
Weekly renal Kt/V
j 0.60 6 0.44 0.37 6 0.36 0.25 6 0.31 0.21 6 0.30 0.10 6 0.19 0.04 6 0.15
Daily urine output (ml)
j 742 6 558 580 6 555 440 6 568 365 6 514 190 6 346 130 6 413
nPNA (g/Kg/d) 1.10 6 0.25 1.09 6 0.23 1.08 6 0.23 1.05 6 0.22 1.04 6 0.20 0.98 6 0.24
Cardiothoracic ratio (%) 51.4 6 7.5 50.1 6 6.7 49.9 6 6.7 49.6 6 6.6 50.5 6 6.2 49.5 6 10.8
Hemoglobin (g/dL) 9.9 6 1.6 9.8 6 1.3 9.8 6 1.4 9.9 6 1.3 9.8 6 1.8 10.0 6 1.5
Blood biochemistry
Total cholesterol (mg/dL)
j 201 6 52 222 6 52 217 6 52 214 6 47 204 6 60 218 6 83
Triglyceride (mg/dL)
j 156 6 111 213 6 151 218 6 171 221 6 166 214 6 155 313 6 431
HDL (mg/dL) 44.0 6 13.6 41.7 6 11.5 41.5 6 15.6 40.3 6 8.9 40.5 6 9.3 40.8 6 9.2
Fasting glucose (mg/dL) 111 6 43 111 6 39 103 6 43 100 6 29 107 6 28 99 6 18
Albumin (g/dL)
j 3.8 6 0.5 4.0 6 0.4 4.0 6 0.4 4.0 6 0.3 4.1 6 0.4 4.0 6 0.2
Urea nitrogen (mg/dL) 65.5 6 22.2 62.8 6 16.0 63.3 6 16.4 62.9 6 15.1 64.1 6 16.9 63.1 6 10.8
Creatinine (mg/dL)
j 9.2 6 3.0 11.0 6 2.9 11.6 6 2.9 11.5 6 3.3 12.3 6 2.5 11.3 6 2.3
NOTE. Data are expressed as mean 6 SD. Conversion factors for units: hemoglobin in g/dL to g/L,610; cholesterol and HDL in mg/dL to mmol/L,60.02586; triglyceride
in mg/dL to mmol/L,60.01129; glucose in mg/dL to mmol/L,60.05551; albumin in g/dL to to g/L,610; urea nitrogen in mg/dL to mmol/L,60.357; creatinine in mg/dL
to mmol/L, 688.4.
Abbreviations: D/P, dialysate-to-plasma; CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis; nPNA, normalized protein nitrogen
appearance; HDL, high-density lipoprotein cholesterol.
*The annual average dialysate glucose concentration prescribed within each year.
**Obtained from all the PD solution prescribed within each year.
***Obtained from the peritoneal equilibration test.
jP,0.05 for the statistical testing between years.
doi:10.1371/journal.pone.0030337.t001
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significantly associated with a better technique survival (Table 3).
By Pearson’s correlation analysis, a higher dialysate glucose weight
was significantly correlated with a higher volume of glucose
solution (r=0.861, P,0.001), and the correlation between the
volume of glucose solution and average dialysate glucose
concentration was much lower (r=0.274, P,0.001). Higher
peritoneal Kt/V (without adding weekly renal Kt/V) was not
persistently associated with a better technique survival. Further
analysis of discretized weekly peritoneal Kt/V (without adding
weekly renal Kt/V) with different cut-off values revealed that the
range between 1.4 and 1.7 was associated with the best technique
survival (Table 3).
Factors determining annual glucose load
Figure 2 shows the distributions of glucose load in our study
population. Considering the gradual increase in the number of
dropouts due to technique failure, we performed multiple linear
regressions to analyze the predictors for annual glucose load
(average dialysate glucose concentration) among patients who
remained on PD at the beginning of that year. We applied PD
year-specific multiple linear regression models, using the stepwise
variable selection method, to analyze the effect of gender, age,
BMI, comorbid diseases, PD modality, icodextrin solution, amino
acid solution, peritoneal characteristics and solute clearance, RRF,
CTR, and results of blood tests. As shown in Table 4, the presence
of DM, higher BMI, lower weekly renal Kt/V, younger age, and
the use of icodextrin solution were significantly correlated with
higher glucose load during most of the years of the study period.
We also observed that the modality of automated PD (APD),
higher CTR, lower peritoneal UF volume, lower serum albumin,
and lower BUN were significantly correlated with higher glucose
load in some years during the study period (Table 4).
Discussion
This is the first detailed survival analysis describing the long-
term effects of glucose load on PD outcomes by applying the
repeatedly measured time-dependent method. In this 7-year
cohort, patients with higher long-term glucose load were
significantly associated with worse actuarial patient survival and
PD technique survival (Table 3). In addition, the prescription of
icodextrin solution was significantly associated with a better PD
technique survival (Table 3). Furthermore, younger age was one of
the main risk factors for high glucose load in long-term PD
(Table 4).
Previous studies on PD patients have shown that the actual
glucose absorption by the peritoneum can be precisely predicted
from the average glucose concentration in the dialysate inflow,
which offers an easy way to evaluate glucose uptake in long-term
PD patients [11]. In the present study, we demonstrated further
that a higher chronic glucose load was significantly associated with
a worse patient survival, as well as a worse technique survival
(Table 3). This result is compatible with our previous report
regarding the harmful effects of the average dialysate glucose
concentration in the initial 6 months after PD commencement [1].
Table 2. Demographic and clinical data of patients who remained alive at the beginning of each year.
Treatment Year
Variable First year Second year Third year Fourth year Fifth year Sixth year
Patient number 173 159 147 99 58 21
Gender(M:F) 87 : 86 81 : 78 75 : 72 46 : 53 29 : 29 9 : 12
Baseline age (years) 54.6 6 15.6 53.9 6 15.2 53.3 6 14.2 51.0 6 12.7 49.9 6 11.9 49.3 6 9.1
Glucose concentration (%)*,
j 1.81 6 0.26 1.70 6 0.51 1.63 6 0.65 1.57 6 0.73 1.48 6 0.91 1.17 6 1.08
Glucose weight (Kg/month)**,
j 4.9 6 1.5 4.7 6 2.0 4.5 6 2.2 4.5 6 2.5 4.1 6 2.8 2.7 6 2.6
Icodextrin solution (L/month)**,
j 3.6 6 14.1 6.8 6 18.5 11.5 6 23.9 8.5 6 20.2 9.7 6 19.8 15.8 6 23.7
Body mass index (Kg/m
2)
j 21.6 6 3.2 22.7 6 3.4 23.1 6 3.4 22.9 6 2.9 22.8 6 2.5 23.2 6 3.3
Comorbid diseases
Diabetes mellitus 37 (21.4) 32 (20.1) 29 (19.7) 13 (13.1) 6 (10.3) 4 (19.0)
Cardiovascular diseases 64 (37.0) 56 (35.2) 47 (32.0) 26 (26.3) 11 (19.0) 6 (28.6)
Weekly renal Kt/V
j 0.60 6 0.44 0.37 6 0.37 0.25 6 0.30 0.21 6 0.29 0.10 6 0.19 0.03 6 0.13
Hemoglobin (g/dL) 9.9 6 1.6 9.75 6 1.29 9.86 6 1.42 9.88 6 1.51 9.82 6 2.00 10.38 6 1.94
Blood biochemistry
Total cholesterol (mg/dL)
j 201 6 52 221 6 52 215 6 52 211 6 48 200 6 59 212 6 80
Triglyceride (mg/dL)
j 156 6 111 213 6 149 212 6 166 218 6 166 206 6 149 282 6 372
Fasting glucose (mg/dL) 111 6 43 113 6 42 104 6 43 100 6 29 106 6 27 101 6 20
Albumin (g/dL)
j 3.8 6 0.5 3.9 6 0.4 4.0 6 0.4 4.0 6 0.4 4.1 6 0.4 4.0 6 0.4
Urea nitrogen (mg/dL) 65.5 6 22.2 62.8 6 16.1 63.8 6 17.3 62.6 6 15.7 63.6 6 17.6 60.6 6 13.4
Creatinine (mg/dL)
j 9.2 6 3.0 10.9 6 3.0 11.5 6 2.9 11.5 6 3.3 12.2 6 2.5 10.5 6 3.0
NOTE. Data are expressed as mean 6 S.D. Conversion factors for units: hemoglobin in g/dL to g/L,610; cholesterol in mg/dL to mmol/L,60.02586; triglyceride in mg/dL
to mmol/L,60.01129; glucose in mg/dL to mmol/L,60.05551; albumin in g/dL to to g/L,610; urea nitrogen in mg/dL to mmol/L,60.357; creatinine in mg/dL to mmol/L,
688.4.
*The annual average dialysate glucose concentration prescribed within each year.
**Obtained from all the PD solution prescribed within each year.
jP,0.05 for the statistical testing between years.
doi:10.1371/journal.pone.0030337.t002
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30337Figure 1. Cumulative survival curves for (A) patient survival and (B) technique survival. All subjects were divided into tertiles (low,
medium, or high glucose load group) according to the average dialysate glucose concentration administered since PD initiation. Survival curves are
constructed by the Kaplan-Meier method and compared by the log-rank test. Subjects with higher glucose load showed worse patient and technique
survivals.
doi:10.1371/journal.pone.0030337.g001
Table 3. Multivariate analyses of the risk factors for patient and technique survival using Cox’s models with repeatedly measured
time-dependent covariates.
Parameter Standard Hazard 95% Confidence
Covariate Estimate (B) Error P Value Ratio Interval
Patient Survival
1:
Baseline age (years) 0.07 0.02 , 0.001 1.07 1.03 - 1.11
Cardiovascular diseases 0.99 0.54 0.07 2.68 0.92 - 7.76
Glucose concentration (%)* 1.83 0.81 0.02 6.23 1.26 - 30.74
Weekly renal Kt/V - 3.18 1.04 0.002 0.04 0.01 - 0.32
Blood urea nitrogen (mg/dL) 0.02 0.01 0.01 1.02 1.004 - 1.04
Creatinine (mg/dL) - 0.40 0.09 , 0.001 0.67 0.56 - 0.80
Technique Survival
2:
Male gender 1.39 0.40 , 0.001 4.03 1.85 - 8.75
Diabetes mellitus 1.53 0.41 , 0.001 4.64 2.07 - 10.38
Glucose concentration (%)* 2.25 0.90 0.01 9.46 1.62 - 55.35
Glucose weight (Kg/month)* - 0.64 0.17 , 0.001 0.53 0.38 - 0.73
Icodextrin solution (L/month)* - 0.02 0.01 0.03 0.98 0.96 - 0.997
Weekly renal Kt/V - 2.03 0.72 , 0.01 0.13 0.03 - 0.53
1.4 ! Weekly peritoneal Kt/V ,1.7 - 1.53 0.63 0.02 0.22 0.06 - 0.74
HDL (mg/dL) - 0.05 0.02 0.02 0.95 0.92 - 0.99
NOTES. Conversion factors for units: HDL in mg/dL to mmol/L, 60.02586; urea nitrogen in mg/dL to mmol/L, 60.357; creatinine in mg/dL to mmol/L, 688.4.
Abbreviations: HDL, high-density lipoprotein cholesterol.
1Cox’s model with 4 repeatedly measured time-dependent covariates (glucose concentration, weekly renal Kt/V, blood urea nitrogen, and creatinine), adjusted
generalized R
2=0.58.
2Cox’s model with 7 repeatedly measured time-dependent covariates (diabetes mellitus, glucose concentration, glucose weight, icodextrin solution, weekly renal Kt/V,
weekly peritoneal Kt/V, and HDL), adjusted generalized R
2=0.31.
*Each subject’s dialysate prescription was represented by (1) the accumulative glucose exposure and (2) the accumulative volumes of icodextrin solution, from the time
of PD initiation to each time at which a PD technique failure or death occurred in the Cox’s models for PD technique failure or mortality.
doi:10.1371/journal.pone.0030337.t003
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related with the consumption of high glucose-containing PD
solution, implying more glucose uptake, poor fluid control, and
more peritoneal damage [3,5,11]. In contrast, prescription of
icodextrin solution is associated with a better PD technique
survival, which may result from the beneficial effects of icodextrin
in improving fluid control and metabolic abnormalities [2,3,14].
Because of the regulations of the health insurance system in
Taiwan, icodextrin solution is prescribed to patients who require
2.5% or 4.25% dextrose solution in more than half of their daily
dialysate volume. This leads to the association between the use of
icodextrin solution and higher average dialysate glucose concen-
tration (Table 4). PD patients require dialysate with higher glucose
concentration if their fluid control is inadequate, thus higher CTR
and lower peritoneal UF volume have some associations with
higher glucose load (Table 4). Daily oral intake in elderly PD
patients may decrease due to diminished appetite, dental
problems, constipation, and increased intra-abdominal pressure
by the dialysate [15]. This may result in less use of PD solution
with high glucose concentration in elderly patients (Table 4).
PD patients with lower levels of serum creatinine or higher
levels of BUN were significantly associated with higher mortality
(Table 3). Serum creatinine is highly correlated with lean body
mass and nutritional condition in patients on chronic dialysis
therapy, and the association between low serum creatinine and
high mortality has been reported in previous studies [16]. A ‘‘U’’-
shaped pattern of the influence of BUN on dialysis patients has
been reported, with higher mortality in patients with BUN over
110 mg/dL or below 60 mg/dL. This phenomenon might result
from malnutrition in low BUN groups and under dialysis in high
BUN groups [16,17]. This explains the association between higher
mortality and lower levels of serum creatinine or higher levels of
BUN (Table 3).
There is a significant correlation between high glucose weight
and high dialysate volume (r=0.861), hence, the beneficial effect
Figure 2. Frequency distribution of average dialysate glucose
concentration in the study population. Average dialysate glucose
concentration of each subject was calculated as: [total glucose weight]/
[total volume of glucose solution] administered since initiation of PD.
doi:10.1371/journal.pone.0030337.g002
Table 4. Multiple linear regression analyses of predictors associated with annual average dialysate glucose concentration










Baseline age (years) — 20.004 6 0.002* 20.003 6 0.002* 20.011 6 0.003** 20.022 6 0.005** 20.020 6 0.007**
Diabetes mellitus 0.226 6 0.040** 0.177 6 0.056** 0.266 6 0.064** 0.186 6 0.093* 0.599 6 0.136** 0.288 6 0.160
1
Body mass index (Kg/m
2) 0.020 6 0.005** 0.028 6 0.006** 0.028 6 0.007** 0.036 6 0.012** — —
Cardiothoracic ratio (%) — 0.783 6 0.336* — 1.328 6 0.493** — —
Weekly renal Kt/V 20.090 6 0.036** 20.174 6 0.055** 20.355 6 0.071** 20.232 6 0.096* — —
Icodextrin solution (kl/month)
b 0.033 6 0.008** 0.025 6 0.008** — — 0.055 6 0.026* 0.107 6 0.019**
Ultrafiltration volume (L)
c ——20.418 6 0.128** 20.479 6 0.139** — —
Automated peritoneal dialysis 0.081 6 0 . 0 4 1 * —————
Albumin (g/dL) 20.079 6 0 . 0 3 1 * * —————
Blood urea nitrogen (mg/dL) — — — 20.004 6 0.002* — —
NOTE. Conversion factors for units: albumin in g/dL to to g/L, 610; urea nitrogen in mg/dL to mmol/L, 60.357.
aThe numbers listed in the table are the least squares estimates of regression coefficients 6 estimates of the corresponding standard errors.
bObtained from all the PD solution prescribed within each year.




1Linear regression model: n=173, R
2=0.4101.
2Linear regression model: n=150, R
2=0.3751.
3Linear regression model: n=129, R
2=0.4534.
4Linear regression model: n=84, R
2=0.4466.
5Linear regression model: n=44, R
2=0.5664.
6Linear regression model: n=22, R
2=0.7284.
doi:10.1371/journal.pone.0030337.t004
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solute clearance. We noted that patients with weekly peritoneal
Kt/V (without adding weekly renal Kt/V) between 1.4 and 1.7
had significantly better technique survivals (Table 3). Similar
results were also reported by Lo et al. They noted a ‘‘V’’ shaped
curve of mortality risk in female anuric PD patients, with the best
survival rates among those with weekly peritoneal Kt/V between
1.67 and 1.86 [18]. According to the guidelines for solute removal
in chronic PD, the weekly total Kt/V (peritoneal Kt/V plus renal
Kt/V) should be at least 1.7 or above [19]. However, there are no
additional beneficial effects on patient outcomes when increasing
the weekly total Kt/V further, and potential adverse effects of
increasing PD dose include increased intraperitoneal pressure,
failure to increase clearance of middle molecules, and increased
exposure to glucose [18].
This study certainly has a few limitations. First, this is a
retrospective cohort analysis, and the causal relationships between
variables and outcomes could be influenced by confounding
factors. Even though we have controlled for several important
covariates, the possibility of residual confounding still remains.
Second, the patient number of our study cohort is slightly limited;
however, the statistical power for testing important hypotheses
should be enough in Cox’s models using repeatedly measured
time-dependent covariates. Third, it is difficult to clearly
distinguish the study population into either continuous ambulatory
PD (CAPD) or APD groups. Patients initiated PD with the
modality of CAPD, and may have shifted between APD and
CAPD according to medical advice and individual family facilities
or convenience. We tried to minimize this limitation by applying
PD modality as a repeatedly measured time-dependent covariate
in the regression analysis. Fourth, although our PD center belongs
to a tertiary referral university hospital with patients from the
whole country, this is a single-center study and the applicability of
our findings to general PD population is still limited. To resolve
these limitations, a prospective, large scale, multi-center random-
ized trial comparing different PD regimens is necessary.
In conclusion, our study demonstrates that long-term glucose
load predicts mortality and technique failure in chronic PD
patients, and the use of icodextrin is associated with a better
technique survival.
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